We assessed the levels of arsenic in drilled wells in Finland and studied the association of arsenic exposure with the risk of bladder and kidney cancers. The study persons were selected fom a register-based cohort of all Finns who had lived at an address outside the municipal d -water system during 1967-1980 (n = 144,627 
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Epidemiologic studies based on high arsenic exposure in Taiwan (5) (6) (7) (8) (9) (10) (11) , Argentina (12, 13) , Japan (14, 15) , and Chile (16) suggest an increased risk of cancer of the urinary organs. The lowest arsenic exposure levels associated with detrimental health effects have been reported in a case-control study in the United States in which the arsenic concentrations in drinking water ranged from 0.5 to 180 pg/L (17) . In that study, no overall association was found between arsenic exposure and cancer risk, but arsenic and cigarette smoking tended to have a synergistic effect on the risk ofbladder cancer.
As much as 12-14% of the Finnish population live outside areas with municipal water supply and use private wells (18) . Water Because drilled wells have been reported to contain essentially higher arsenic concentrations than other types of wells (22) , only those addresses where drinking water from drilled wells was consumed before the year 1981 were selected for further study ( Table  1 ). The use of the drilled wells for drinking water had started before 1981 but may have continued until 1996. Local health inspectors collected well-water samples from the selected addresses of 509 subjects.
Those 380 subjects (76% of cases and 74% of reference cohort eligible) for whom arsenic exposure could be estimated (i.e., the well-water sample was available and well water had been used as drinking water) were induded in the final analysis ( Arsenic measurements. The well-water samples were collected between July and November 1996. The samples were collected in random order, blinded in regard to the case-referent status. Each sample was filtered through a 0.45-pm membrane filter and acidified with HNO3 at the sample site. The samples were sent to the laboratory within 2 days.
Total arsenic was determined by Perkin Elmer Sciex Elan 6000 inductively coupled plasma mass spectrometry (Perkin-Elmer, Rotkreuz, Switzerland). The detection limit for arsenic was 0.05 pg/L. The performance of the analytical method was monitored continuously including certified reference materials within the analytical batches. Sixty-four of the samples were analyzed twice. The median coefficient of variation was 2.2%.
To evaluate the validity ofwater sampling, two water samples were taken from 36 randomly selected wells at two different times (on average 31 days apart; range 2 hr-88 days). The arsenic concentrations in the original samples and field duplicates were not significandy different (median of the absolute difference between two samples was 0.02 ig/L; p = 0.2 in the Wilcoxon signed ranks test).
Estimates of arsenic exposure. The arsenic exposure for cases with cancer and members of reference cohort was estimated in two periods: from the third to ninth calendar years (shorter latency) and from the tenth or earlier calendar years (longer latency) prior to the cancer diagnosis (or the respective year for referent persons).
The daily dose of arsenic from drinking water was calculated from the arsenic concentration of well water and from the reported consumption of well water in the 1970s. If questionnaire data were not available, the consumption of drinking water was set as the mean from the reference cohort. Men consumed on average 1.6 L/day (range 0.1-4.5 L/day) and women consumed 1.6 L/day (0.6-3.0 L/day) of well water. At two addresses (one member of the reference cohort and one kidney cancer case), water samples from two drilled wells were available. In those cases, the higher arsenic concentration was included in the calculations of arsenic concentration and daily dose, and actual use for cumulative exposure.
Consumption of well water started on average in 1970 [standard deviation (SD) = 8 years] and stopped in 1990 (SD = 6 years). The cumulative dose was defined as an integral of duration and intensity of arsenic exposure from well water. The cumulative dose for the shorter latency was calculated from the beginning of the use of well water until 2 years before the cancer diagnosis. For the longer latency, the cumulative dose was calculated until 10 years before the cancer diagnosis. The drinking water before the beginning and after the end of the consumption of the well water was considered as null. Exposure from other sources was not taken into account.
Statistical analyses. The study was based on the case-cohort design described by Prentice (21) and Barlow (23) . In the analysis of a case-cohort study, the risk set at each event time (year of cancer diagnosis) consists of the case that failed at that particular time and all members of the reference cohort who were at risk at the time. Members of the reference cohort were weighted in inverse proportion to the sampling fraction (4,590/ 144,627). The robust variance matrix was estimated using SAS/IML (Interactive Matrix Programming Language; SAS Institute, Cary, NC). The 95% confidence intervals (CIs) were calculated from the robust variance estimates and standard errors.
Risk ratios (RRs) were estimated using PHREG (Cox's Multivariable Proportional Regression Analysis) procedure of SAS, calculated both for continuous and categorical arsenic exposure (class limits set roughly at the 50th and 75th percentiles of the reference cohort). To limit the influence of the few observations with high levels of arsenic, we estimated linear models after log-transforming the arsenic exposure indicator. Cigarette smoking is an established risk factor for both bladder and kidney cancers (24, 25) and high body mass index (BMI) is an established risk factor for kidney cancer (26) . The multivariate models of bladder cancer were adjusted for age, sex, and smoking (never smoked, ex-smoker stopped smoking before 1970, smoker in the 1970s). The multivariate models of kidney cancer were adjusted for age, sex, smoking, and BMI [< 25, 2 25 weight in kilograms/(height in meters)2]. Subjects with missing data on smoking and BMI (Table 3) were included in the models as a separate category. Use of analgesics and diuretics in the 1970s and education were not associated with the risk of bladder or kidney cancers and were therefore not included in the final models.
Results
Arsenic concentrations in reference wells. The arsenic concentrations in the wells of the reference cohort ranged from < 0.05 to 64 pg/L (median 0.14 jig/L; CI, < 0.05-4.5; Table 4 ). Characteristics of cases versus controls. The study population was a demographically rather homogeneous group of people with a mainly agricultural background ( Table 2 ). The residence locations of cancer cases and referents did not differ systematically ( Figure  1 ). Residential mobility was remarkably low; 71% of those alive in 1996 still lived in the same place where they had lived in 1967. Cigerette smoking in the 1970s was more common among the cancer cases than among the reference cohort; the association between smoking and bladder cancer was statistically significant (Tables 3 and 5) .
Arsenic and bladder cancer. We observed an increasing trend for arsenic concentrations in drinking water and the daily dose of arsenic with shorter latency, but not with longer latency (Table 6 ). The point estimate for arsenic concentration > 0.5 jig/L was statistically significantly elevated. The association between arsenic exposure and bladder cancer tended to be stronger among those who smoked in the 1970s (Table 7) .
Arsenic and kidney cancer. We found no evidence for an association between arsenic concentration, daily dose, or cumulative dose and the risk of kidney cancer (Table 8) .
Discussion
High concentrations of arsenic in drilled wells were previously detected in southwestern Finland (19, 22) , and geochemical surveys (20) (27) .
We have previously shown that the steady-state current arsenic exposure can be adequately estimated by asking subjects about daily drinking-water consumption at home (19) . In the present study, however, we were interested in the water consumption in the 1970s, which is more prone to misclassification and affected by recall bias. The earlier arsenic concentrations were considered to be the same as they were at the time of the sampling, which may introduce errors. No published data on annual variations of arsenic concentrations in well water in Finland were available, but the concentrations may fluctuate depending on the water catchment basin of the well (i.e., the level of groundwater). Some studies have, however, reported that arsenic concentrations in wells in arsenic-rich areas remain relatively constant for decades (11, 12) .
The calculation of cumulative dose is more sensitive to errors than daily dose or concentration. The year of beginning of well-water use may not have been recalled adequately, and an error in the duration of well-water use has a significant influence on the amount of cumulative dose. The arsenic concentrations in drinking water other than those measured from drilled wells were considered zero. This may introduce misclassification in the cumulative dose, especially when arsenic concentrations in drilled wells were as low as in other sources of drinking water. This misclassification, however, is likely to be nondifferential.
The arsenic doses found in previous studies (5) (6) (7) (8) (9) (10) (11) (12) on arsenic exposure and cancer in urinary organs were much higher than those found in this study. In the present study, we used individual arsenic exposure variables instead of area-based measures used in most previous studies. Studies in Taiwan have suggested that cancers of the bladder, kidney, lung, liver, skin, and possibly some other sites are associated with drinking-water arsenic concentrations ranging from 10 to 1,800 pg/L (5) (6) (7) (8) 28) and from 350 to 1,140 pg/L (9) . Furthermore, ingested arsenic exposure has been associated with the increased risk of cancers in urinary organs in Argentina, Japan, and Chile. The lowest cut points of the categorical arsenic concentrations were 40 ,ug/L in Argentina (12, 13) and 50 pg/L in Japan (14, 15) . In Chile, the regional average arsenic concentrations in drinking water ranged from 43 to 570 pg/L (16) . The only earlier nonecological study on bladder cancer risk and lower arsenic concentrations (from 0.5 to 180 jig/L) in drinking water in the United States did not show a clear association (12) . A follow-up study among English patients showed that orally administered arsenic medication with substantially higher doses was associated with an increase in bladder cancer mortality (29) .
We found some suggestion of an increased bladder cancer risk associated with low arsenic exposure levels in the present study. The risk estimates for bladder cancer and arsenic concentration, as well as daily dose from 2 to 9 years before the cancer diagnosis, were above unity, and there was some indication of a dose response. A statistically significantly elevated risk of bladder cancer was observed for arsenic concentrations > 0.5 ,pg/L. Exposures earlier than 10 years before cancer diagnoses did not show an association with bladder cancer risk. Hence, relatively recent arsenic exposure appears to be more relevant for bladder cancer risk. This is in concordance with the hypothesis that arsenic compounds act as promoters and/or co-carcinogens in the late stage of carcinogenesis (30-32. Cigarette smoking in the 1970s was more common among bladder cancer cases than among referents; this is in agreement with previous studies which reported that smoking is associated with bladder cancer (25) . In addition, there was some suggestion of a synergistic effect of arsenic and smoking (Table  7 ). This finding is consistent with earlier studies in which elevated arsenic exposure tended to increase the bladder cancer risk (9,17) among smokers. Experimental studies also suggest that arsenic compounds promote the carcinogenicity and genotoxicity of the known carcinogens and genotoxic compounds (31) (32) (33) .
In this study, no association was observed between kidney cancer and arsenic exposure from drinking water. In earlier epidemiologic studies, an association between arsenic exposure and kidney cancer was somewhat weaker than the association to bladder cancer (6) (7) (8) 10, 11, 13, 16) .
It is difficult to compare the cancer risks between various studies because arsenic exposure has been expressed in different ways and because the extension and duration of arsenic exposure in these studies are different. The differences in the effect estimates in the studies may also be due to the differences in Nutritional factors may modify the metabolism and possibly carcinogenicity of arsenic. Selenium is an important anticarcinogen (34) , and it has been suggested to reduce the toxicity of arsenic (35) and to inhibit the methylation of inorganic arsenic in vitro (36) . Therefore, deficiency of selenium may increase the cancer risk of arsenic. In Finland, the daily intake of selenium (average 30 jig) (37) was below the recommended 50-200 pg (38) before selenium supplementation in fertilizers started in 1985.
The crude risk ratios of arsenic exposure and bladder cancer increased only slightly after adjustment for smoking. This suggests that, although the proportion of missing data on smoking was large, the results are probably not confounded by smoking. We believe that serious differential misclassification is unlikely in the present study. There were no differences between cases and noncases in the sampling or analyzing procedure. Furthermore, there were no differences in the demographic parameters of the eligible and the final study populations. It has previously been shown that relatives are able to provide rather reliable information on smoking and other major demographic and lifestyle factors (39) (40) (41) .
Our results show that high arsenic levels in Finnish drilled wells used in the 1970s were uncommon and exposure through drinking water was low. We found no statistically significant association between arsenic and risk of kidney cancer. However, consistent with earlier studies, there was some evidence for an increased risk of bladder cancer associated with arsenic exposure 2-9 years before the diagnosis and some suggestion of a synergistic effect between arsenic and smoking. Due to low exposure levels in the present study, the positive association between arsenic exposure and risk of bladder cancer was not expected, and the role of bias and chance needs to be carefullly considered. Only data for shorter latency and known smoking status are presented. 
